Search

Displaying results 9821 - 9830 of 10000 in total
  1. Drug

    Pyrrolidone

    go.drugbank.com/drugs/DB19152
    Experimental

    Pyrrolidone is under investigation in clinical trial NCT05444998 (Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for Her2+breast Cancer).

  2. Drug

    Navafenterol

    go.drugbank.com/drugs/DB19195
    Investigational

    Navafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).

  3. Drug

    Cannabidiolic acid

    go.drugbank.com/drugs/DB19261
    Investigational

    Cannabidiolic acid is under investigation in clinical trial NCT04103814 (Effect of Topical CBD Cream for Degenerative Hallux Disorders).

  4. Drug

    Medical Cannabis

    go.drugbank.com/drugs/DB14009
    Investigational

    While cannabis in its natural plant form is currently used "off-label" for the management of many medical conditions, THC is currently commercially available in synthetic form as [DB00486], as purified … wave of legalization in North America has changed public and medical opinion on its use.

  5. Drug

    EGT-101

    go.drugbank.com/drugs/DB17645
    Experimental

    Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.[L45919] … EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene.

  6. Drug

    Fosgonimeton

    go.drugbank.com/drugs/DB21516
    Investigational

    Fosgonimeton is a small molecule drug. Fosgonimeton is under investigation in clinical trial NCT05511558 (A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)).

  7. Drug

    IDM-1

    go.drugbank.com/drugs/DB05292
    Experimental

    It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc. … IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer.

  8. Drug

    SR-9009

    go.drugbank.com/drugs/DB14013
    Experimental

    SR-9009 is a REV-ERB agonist. … SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues

  9. Drug

    ALT-P1

    go.drugbank.com/drugs/DB18485
    Investigational

    ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.

  10. Drug

    GLPG-1205

    go.drugbank.com/drugs/DB15346
    Investigational

    GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)).